Brexit Already Affecting UK Regulator’s Role In Marketing Authorizations
Executive Summary
A recent stakeholder meeting at the EMA heard that because of Brexit, the UK will soon no longer be able to play the role of rapporteur for initial EU marketing authorization applications. Meanwhile, the EMA is working with the other 27 EU member states to ensure an “orderly redistribution” of the work currently done by the UK regulator, the MHRA.
You may also be interested in...
Massive Reallocation of UK Rapporteurships Likely As EMA Plans For Future; UK’s Interim Role Uncertain
If Brexit means the UK no longer plays a part in the EU drug regulatory system, responsibility for the ongoing oversight of almost one in four of all the human medicines that have ever been approved under the centralized procedure will have to be reassigned from the UK to other member states. What Brexit means for the UK’s role as a key player in the regulatory system in the meantime is the subject of speculation.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.